Journal Menu
► ▼ Journal Menu-
- Vaccines Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserNeed Help?
Announcements
4 March 2026
MDPI’s 2025 Best Paper Awards—Award-Winning Papers Announced
MDPI is honored to announce the recipients of the 2025 Best Paper Awards, celebrating exceptional research for its scientific merit and broad impact. After a rigorous evaluation process conducted by Academic Editors, this year’s awards showcase papers that stand out for their innovation, relevance, and high-quality presentation.
Out of a highly competitive pool, 396 winning papers have been recognized for their exceptional contributions. We congratulate these authors for pushing the boundaries of their respective disciplines.
At MDPI, we are dedicated to broadening the reach of innovative science. To learn more about the award-winning papers and explore research projects in your field of study, please visit the following links:
- Biology and Life Sciences;
- Business and Economics;
- Chemistry and Materials Sciences;
- Computer Sciences and Mathematics;
- Engineering;
- Environmental and Earth Sciences;
- Medicine and Pharmacology;
- Social Sciences, Arts and Humanities;
- Physical Sciences;
- Public Health and Healthcare.
About MDPI Awards:
To reward the global research community and enhance academic dialogue, MDPI journals regularly host award programs across diverse scientific disciplines. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and whose work drives the advancement of their fields.
Explore the Best Paper Awards open for participation, please click here.
6 November 2025
MDPI Launches the Michele Parrinello Award for Pioneering Contributions in Computational Physical Science
MDPI is delighted to announce the establishment of the Michele Parrinello Award. Named in honor of Professor Michele Parrinello, the award celebrates his exceptional contributions and his profound impact on the field of computational physical science research.
The award will be presented biennially to distinguished scientists who have made outstanding achievements and contributions in the field of computational physical science—spanning physics, chemistry, and materials science.
About Professor Michele Parrinello
"Do not be afraid of new things. I see it many times when we discuss a new thing that young people are scared to go against the mainstream a little bit, thinking what is going to happen to me and so on. Be confident that what you do is meaningful, and do not be afraid, do not listen too much to what other people have to say.”
——Professor Michele Parrinello
![]() |
Born in Messina in 1945, he received his degree from the University of Bologna and is currently affiliated with the Italian Institute of Technology. Professor Parrinello is known for his many technical innovations in the field of atomistic simulations and for a wealth of interdisciplinary applications ranging from materials science to chemistry and biology. Together with Roberto Car, he introduced ab initio molecular dynamics, also known as the Car–Parrinello method, marking the beginning of a new era both in the area of electronic structure calculations and in molecular dynamics simulations. He is also known for the Parrinello–Rahman method, which allows crystalline phase transitions to be studied by molecular dynamics. More recently, he has introduced metadynamics for the study of rare events and the calculation of free energies. |
For his work, he has been awarded many prizes and honorary degrees. He is a member of numerous academies and learned societies, including the German Berlin-Brandenburgische Akademie der Wissenschaften, the British Royal Society, and the Italian Accademia Nazionale dei Lincei, which is the major academy in his home country of Italy.
Award Committee
![]() |
The award committee will be chaired by Professor Xin-Gao Gong, a computational condensed matter physicist, academician of the Chinese Academy of Sciences, and professor at the Department of Physics, Fudan University. Professor Xin-Gao Gong will lead a panel of several senior experts in the field to oversee the evaluation and selection process. The Institute for Computational Physical Sciences at Fudan University (Shanghai, China), led by Professor Xin-Gao Gong, will serve as the supporting institute for the award. |
"We hope the Michele Parrinello Award will recognize scientists who have made significant contributions to the field of computational condensed matter physics and at the same time set a benchmark for the younger generation, providing clear direction for their pursuit—this is precisely the original intention behind establishing the award."
——Professor Xin-Gao Gong
The first edition of the award was officially launched on 1 November 2025. Nominations will be accepted before the end of March 2026. For further details, please visit mparrinelloaward.org.
About the MDPI Sustainability Foundation and MDPI Awards 
The Michele Parrinello Award is part of the MDPI Sustainability Foundation, which is dedicated to advancing sustainable development through scientific progress and global collaboration. The foundation also oversees the World Sustainability Award, the Emerging Sustainability Leader Award, and the Tu Youyou Award. The establishment of the Michele Parrinello Award will further enrich the existing award portfolio, providing continued and diversified financial support to outstanding professionals across various fields.
In addition to these foundation-level awards, MDPI journals also recognize outstanding contributions through a range of honors, including Best Paper Awards, Outstanding Reviewer Awards, Young Investigator Awards, Travel Awards, Best PhD Thesis Awards, Editor of Distinction Awards, and others. These initiatives aim to recognize excellence across disciplines and career stages, contributing to the long-term vitality and sustainability of scientific research.
Find more information on awards here.
25 March 2026
Acknowledging the Contributions of Our Reviewers in 2025
As a pioneer in open access publishing, MDPI maintains rigorous publication standards. This mission relies on the dedication and expertise of our reviewers, who invest their time and knowledge to ensure the quality and integrity of the research we publish.
In 2025, over 209,000 reviewers contributed to the peer-review process at MDPI, providing more than 1.3 million review reports for our journals. To express our gratitude, MDPI’s Reviewer Recognition Program highlights reviewers across over 400 journals, featuring those who have assessed at least one manuscript and agreed to be acknowledged.
In addition, MDPI has identified its Top 1000 Reviewers of 2024 to recognize those whose expertise, dedication, and thoughtful evaluations were particularly outstanding.
Many journals have also established Outstanding Reviewer Awards to honor our reviewers’ commitment to publication excellence. Together with the Exceptional Reviewer List, we showcase the importance of reviewers’ work and their time and dedication.
These initiatives serve to express our deepest appreciation and gratitude towards the whole reviewer community. In recognition of their contributions, we also welcome new researchers to join this community. If you would like to contribute to open access publishing, learn more about the reviewers’ benefits and sign up to join us.
24 March 2026
World Tuberculosis Day 2026—“Yes! We Can End TB: Led by Countries, Powered by People.”, 24 March 2026
Tuberculosis is a disease that is both preventable and treatable, significantly affecting people’s health and quality of life worldwide. Every year, we commemorate World Tuberculosis Day to raise public awareness of the devastating health, social, and economic consequences of tuberculosis (TB) and to intensify efforts to end the global TB epidemic. The date signifies the day in 1882 when Dr. Robert Koch announced his discovery of the bacterium responsible for TB, which paved the way for diagnosing and curing this disease.
The theme of World TB Day 2026, “Yes! We can End TB! Led by Countries, Powered by People”, is a bold call to action and a message of hope, affirming that it is possible to get back on track and turn the tide on the TB epidemic, even in a challenging global environment. With decisive country leadership, increased domestic and international investment, rapid uptake of new WHO recommendations and innovations, accelerated action, and strong multisectoral collaboration, ending TB is not just aspirational—it is achievable.
We hope that established journals in the fields of biology, life sciences, medicine, and pharmacology at MDPI will continue to serve as a communication platform for innovative ideas regarding prevention and treatment.
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
|
|
“Trends in Tuberculosis Incidence and Mortality in South Africa and Bulgaria (2000–2023): The Impact of Income, Poverty, Unemployment, and Universal Health Coverage”
by Siyabonga Kave, Joana Simeonova, Antoniya Yanakieva, Alexandrina Vodenitcharova, Denisha Govender, Yandisa Sikweyiya and Nelisiwe Khuzwayo
Epidemiologia 2026, 7(2), 39; https://doi.org/10.3390/epidemiologia7020039
“Humoral Immune Activation Against Mycobacterium avium subsp. paratuberculosis Through Oral Immunization with Engineered Salmonella”
by Azar Motamedi Boroojeni, Nikoo Veiskarami, Elena Rita Simula, Leonardo Antonio Sechi and Abdollah Derakhshandeh
Bacteria 2025, 4(3), 47; https://doi.org/10.3390/bacteria4030047
“History of Pulmonary Tuberculosis Accelerates Early Onset and Severity of COPD: Evidence from a Multicenter Study in Romania”
by Ramona Cioboata, Silviu Gabriel Vlasceanu, Denisa Maria Mitroi, Ovidiu Mircea Zlatian, Mara Amalia Balteanu, Gabriela Marina Andrei, Viorel Biciusca and Mihai Olteanu
J. Clin. Med. 2025, 14(17), 5980; https://doi.org/10.3390/jcm14175980
“Integration of AI and ML in Tuberculosis (TB) Management: From Diagnosis to Drug Discovery”
by Sameeullah Memon, Shabana Bibi and Guozhong He
Diseases 2025, 13(6), 184; https://doi.org/10.3390/diseases13060184
“Three-Dimensional-Printed Isoniazid Chewable Gels for On-Demand Latent Tuberculosis Treatment in Children”
by Amanda de O. E. Moreira, Lêda Maria S. Azevedo Neta, Márcia Pietroluongo, Ana Paula dos S. Matos, Beatriz B. Correa, Beatriz H. Ortiz, André da S. Guimarães, Marcio Nele, Carollyne M. Santos, Ana Elizabeth C. Fai et al.
Pharmaceutics 2025, 17(5), 658; https://doi.org/10.3390/pharmaceutics17050658
“Prevalence and Associated Factors of Latent Tuberculosis Infection Among Healthcare Workers in a Mexican Tertiary Care Hospital”
by José Ángel Hernández-Mariano, Mónica Alethia Cureño-Díaz, Verónica Fernández-Sánchez, Estibeyesbo Said Plascencia-Nieto, Dulce Milagros Razo-Blanco-Hernández, Claudia Vázquez-Zamora, Víctor Hugo Gutiérrez-Muñoz, Beatriz Leal-Escobar, Erika Gómez-Zamora and Yanelly Estrella Morales-Vargas
Diseases 2025, 13(6), 173; https://doi.org/10.3390/diseases13060173
“The Complex Relationship Between Tuberculosis and Hyperglycemia”
by Michelle Byers and Elizabeth Guy
Diagnostics 2024, 14(22), 2539; https://doi.org/10.3390/diagnostics14222539
“The Role of mTOR in Mycobacterium tuberculosis Infection”
by Ami Patel, Lannhi Nguyen, Christina Shea, Sunjum Singh and Vishwanath Venketaraman
Biomedicines 2024, 12(10), 2238; https://doi.org/10.3390/biomedicines12102238
“Tuberculosis-Induced Immune-Mediated Necrotizing Myopathy: A Challenging Case Scenario in a Non-Endemic Country”
by Agnese Colpani, Davide Astorri, Andrea De Vito, Giordano Madeddu, Sandro Panese and Nicholas Geremia
Reports 2024, 7(4), 82; https://doi.org/10.3390/reports7040082
“Adherence to Short-Duration Treatment (3HP) for Latent Tuberculosis among International Migrants in Manaus, Amazonas: Evaluation of the Efficacy of Different Treatment Modalities”
by Yan Mathias Alves, Thaís Zamboni Berra, Sonia Vivian de Jezus, Vânia Maria Silva Araújo, Jair dos Santos Pinheiro, Lara Bezerra de Oliveira de Assis, Marvis Canelonez, Daniel Souza Sacramento, Freddy Perez, Ethel Leonor Noia Maciel et al.
Microorganisms 2024, 12(8), 1629; https://doi.org/10.3390/microorganisms12081629
“A Multidisciplinary Approach to the Management of Eales Disease: A Case Report and Review of the Literature”
by Maria Filoftea Mercut, Oana Maria Ică, Cornelia Andreea Tănasie, Răzvan Mercuț, Carmen Luminița Mocanu, Andreea Mihaela Nicolcescu and Ciprian Danielescu
J. Pers. Med. 2024, 14(3), 235; https://doi.org/10.3390/jpm14030235
“Mycobacterium tuberculosis Deficient in PdtaS Cytosolic Histidine Kinase Displays Attenuated Growth and Affords Protective Efficacy against Aerosol M. tuberculosis Infection in Mice”
by Kelly A. Prendergast, Gayathri Nagalingam, Nicholas P. West and James A. Triccas
Vaccines 2024, 12(1), 50; https://doi.org/10.3390/vaccines12010050
|
“Novel Therapeutic Agents and Innovative Delivery Systems Against Infectious Diseases” |
“Genomic Epidemiology & Drug Resistance in Mycobacterium tuberculosis” |
![]() |
![]() |
|
“Mycobacterial Infections and Human Disease: Emerging Mechanisms and Therapeutic Strategies/Boundaries” |
“Recent Advances in Molecular and Cellular Approaches to Tuberculosis Pathogenesis, Treatment and Prevention” |
![]() |
![]() |
|
“Personalized Medicine in Epidemiology and Infectious Diseases” |
“Biomolecules in Mycobacterial Pathogenesis, Host–Pathogen Interactions, and Antimicrobial and Therapeutic Approaches” |
![]() |
![]() |
20 March 2026
Meet Us at the Asia–Pacific Vaccine and Immunotherapy Congress 2026 (APVIC 2026), 6–8 May 2026, Biopolis, Singapore
Conference: Asia–Pacific Vaccine and Immunotherapy Congress 2026 (APVIC 2026)
Date: 6–8 May 2026
Location: Matrix, Biopolis, Singapore
Join us in Singapore for the Asia–Pacific Vaccine and Immunotherapy Congress (APVIC) 2026!
This international congress brings together leading scientists, clinicians, researchers, and industry experts working at the forefront of vaccinology, immunology, and immunotherapy.
APVIC 2026 will serve as a dynamic platform for knowledge exchange and collaboration, covering cutting-edge research in vaccine development, immune responses, infectious diseases, cancer immunotherapy, translational medicine, and public health strategies. The conference aims to foster interdisciplinary dialogue and strengthen partnerships across academia, healthcare, and industry in the Asia–Pacific region and beyond.
Don’t miss this opportunity to connect with peers, share insights, and contribute to the advancement of vaccine and immunotherapy research. Register now and be part of this vibrant scientific community.
The following journals will represent MDPI at the conference:
If you are planning to attend APVIC 2026, feel free to reach out and start a conversation with us. Our team looks forward to meeting you in person and will be happy to discuss publishing opportunities or answer any questions that you may have.
For more information about the congress, please visit https://www.apvic.org/.
16 March 2026
Vaccines | Notable Papers Published in 2025 in the “Human Papillomavirus Vaccines” Section
1. “Barriers to and Facilitators for Accessing HPV Vaccination in Migrant and Refugee Populations: A Systematic Review”
by Davide Graci, Nicolò Piazza, Salvatore Ardagna, Alessandra Casuccio, Anton Drobov, Federica Geraci, Angelo Immordino, Alessandra Pirrello, Vincenzo Restivo, Riccardo Rumbo et al.
Vaccines 2024, 12(3), 256; https://doi.org/10.3390/vaccines12030256
Full text available online: https://www.mdpi.com/2076-393X/12/3/256
2. “Human Papillomavirus (HPV) Vaccine Coverage and Confidence in Italy: A Nationwide Cross-Sectional Study, the OBVIOUS Project”
by Marco Montalti, Aurelia Salussolia, Angelo Capodici, Francesca Scognamiglio, Zeno Di Valerio, Giusy La Fauci, Giorgia Soldà, Maria Pia Fantini, Anna Odone, Claudio Costantino et al.
Vaccines 2024, 12(2), 187; https://doi.org/10.3390/vaccines12020187
Full text available online: https://www.mdpi.com/2076-393X/12/2/187
3. “Therapeutic Vaccines for HPV-Associated Cervical Malignancies: A Systematic Review”
by Souhail Alouini and Chantal Pichon
Vaccines 2024, 12(4), 428; https://doi.org/10.3390/vaccines12040428
Full text available online: https://www.mdpi.com/2076-393X/12/4/428
4. “Healthcare Professionals’ Perspectives on HPV Recommendations: Themes of Interest to Different Population Groups and Strategies for Approaching Them”
by Carlos Murciano-Gamborino, Javier Diez-Domingo and Jaime Fons-Martinez on behalf of the PROTECT-EUROPE Consortium
Vaccines 2024, 12(7), 748; https://doi.org/10.3390/vaccines12070748
Full text available online: https://www.mdpi.com/2076-393X/12/7/748
5. “Impact of HPV Vaccination on the Incidence of High-Grade Cervical Intraepithelial Neoplasia (CIN2+) in Women Aged 20–25 in the Northern Part of Norway: A 15-Year Study”
by Marte Pettersen Mikalsen, Gunnar Skov Simonsen and Sveinung Wergeland Sørbye
Vaccines 2024, 12(4), 421; https://doi.org/10.3390/vaccines12040421
Full text available online: https://www.mdpi.com/2076-393X/12/4/421
6. ““I Thought It Was Better to Be Safe Than Sorry”: Factors Influencing Parental Decisions on HPV and Other Adolescent Vaccinations for Students with Intellectual Disability and/or Autism in New South Wales, Australia”
by Allison Carter, Christiane Klinner, Alexandra Young, Iva Strnadová, Horas Wong, Cassandra Vujovich-Dunn, Christy E. Newman, Cristyn Davies, S. Rachel Skinner, Margie Danchin et al.
Vaccines 2024, 12(8), 922; https://doi.org/10.3390/vaccines12080922
Full text available online: https://www.mdpi.com/2076-393X/12/8/922
7. ““You Don’t Know If It’s the Truth or a Lie”: Exploring Human Papillomavirus (HPV) Vaccine Hesitancy among Communities with Low HPV Vaccine Uptake in Northern California”
by Julie H. T. Dang, Alexandra Gori, Lucy Rios, Angelica M. Rolon, Jingwen Zhang and Moon S. Chen, Jr.
Vaccines 2024, 12(4), 372; https://doi.org/10.3390/vaccines12040372
Full text available online: https://www.mdpi.com/2076-393X/12/4/372
8. “School Teachers’ Perceptions of Adolescent Human Papillomavirus (HPV) Vaccination: A Systematic Review”
by Jihye Choi, Efrat K. Gabay and Paula M. Cuccaro
Vaccines 2024, 12(4), 361; https://doi.org/10.3390/vaccines12040361
Full text available online: https://www.mdpi.com/2076-393X/12/4/361
9. “Analysis of Implementation Strategies for Nationwide HPV Vaccination Programs Across European Union Countries”
by Wojciech Miazga, Tomasz Tatara, Mariusz Gujski, Janusz Ostrowski, Jarosław Pinkas and Urszula Religioni
Vaccines 2024, 12(12), 1325; https://doi.org/10.3390/vaccines12121325
Full text available online: https://www.mdpi.com/2076-393X/12/12/1325
10. “Overcoming HPV Vaccine Hesitancy in Japan: A Narrative Review of Safety Evidence, Risk Communication, and Policy Approaches”
by Takayuki Takahashi, Megumi Ichimiya, Misa Tomono, Rio Minoura, Takahiro Kinoshita, Yousuke Imanishi, Masahiko Sakamoto, Makiko Mitsunami, Mihyon Song, Kanako Inaba et al.
Vaccines 2025, 13(6), 590; https://doi.org/10.3390/vaccines13060590
Full text available online: https://www.mdpi.com/2076-393X/13/6/590
13 March 2026
Prof. Dr. Ger Rijkers Appointed Editor-in-Chief of Vaccines
We are pleased to announce the appointment of Prof. Dr. Ger Rijkers as the new Editor-in-Chief of Vaccines (ISSN: 2076-393X).
Name: Prof. Dr. Ger Rijkers
Affiliation: Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, the Netherlands
Interests: immunology; immunodeficiency; vaccination; pneumococcal pneumonia; SARS-CoV-2
Prof. Dr. Ger Rijkers is Emeritus Professor in Biomedical and Life Sciences, Department of Health, Cognition, and Behavior at University College Roosevelt (UCR), Middelburg, the Netherlands. At UCR, he has been head of the Science Department and coordinator of the premedical program. During the academic year of 2025-2026, he is teaching the courses Mechanisms of Disease and Infection and Immunity.
Prof. Dr. Ger Rijkers studied biology at Wageningen University, the institute where he also completed his PhD in 1980 (on the immune system of cyprinid fish). He then specialized as a medical immunologist at the Wilhelmina Children’s Hospital and the Faculty of Medicine of Utrecht University. During this specialization, he spent two sabbaticals at the laboratories of Don Mosier (Philadelphia PA) and John Cambier (Denver CA), respectively. He has worked as head of the laboratory of pediatric immunology and senior researcher in the field of mucosal immunology at the Department of Gastrointestinal Surgery of Utrecht University and of Radboud University. In the St Antonius Hospital in Nieuwegein, he has supervised studies on vaccination of patients with respiratory diseases. During the COVID-19 pandemic, he worked as a medical immunologist and senior scientist at the Laboratories of Medical Microbiology and Immunology of the St Elizabeth Hospital in Tilburg and the Admiral De Ruyter Hospital in Goes, the Netherlands. As a researcher and academic, Ger Rijkers studies the interaction between the human immune system and micro-organisms of the respiratory and gastrointestinal tract in immunoregulation and healthy ageing (at the beginning and end of life).
He has supervised over 40 PhD students and published over 400 papers in peer-reviewed scientific journals, as well as a textbook on immunology (3rd edition published in August 2023). He has served as Editor-in-Chief and Section Editor of several (bio)medical journals.
Ger Rijkers has been married to Riky Lievendag for 46 years. He has three adult sons and four grandchildren. When not working, he studies, with his brother Jan Rijkers, the origin and meaning of the elephant in the painting The Garden of Earthly Delights by Jheronimus Bosch.
The following is a short Q&A with Prof. Dr. Ger Rijkers, who shared his vision for the journal with us, as well as his views of the research area and open access publishing:
1. What appealed to you about the journal that made you want to take the role as its Editor-in-Chief?
Before I was approached to become Editor-in-Chief of Vaccines, I already knew the journal very well. I have published in regular issues, as well as Special Issues. My predecessor, Prof. Dr. Ralph Tripp, has done an excellent job bringing the journal forward to where it now stands. I am proud to be allowed to stand in his footsteps.
2. What is your vision for the journal?
Vaccines has a broad scope, ranging from the fundamental aspects of identifying the antigens and epitopes which could lead to protective immunity to overcoming vaccine hesitance or even resistance. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. The journal could play a role here, maybe by translating the outcome of studies in plain language, addressing a lay audience.
While, as indicated above, the political climate has changed, the meteorological climate is also changing. This will inevitably have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.
3. What does the future of this field of research look like?
We are proud to welcome and present the research and perspectives of many researchers and policy makers across the world, working on all aspects of vaccines and vaccination. We thus strive to contribute to further improvement of the health of all people in the world, especially the most vulnerable. Thus far, vaccination has been mainly used for protection against infectious diseases. For some of them, vaccination has been extremely successful and has led, or can lead, to complete eradication of the disease. For others, especially AIDS, malaria, and parasitic infections, there is a long way to go. Anti-tumor vaccines and vaccines against autoimmune diseases are in early stages of development.
4. What do you think of the development of open access research in the publishing field?
I recall the situation from long, long ago when I published my first papers. At that time, as an author you could order reprints of your paper. Afterwards, you received postcards from all over the world, mostly low-income countries, of fellow researchers requesting a reprint of your paper. If your library did not have a subscription to a wide range of journals, you just could not keep up with your field. “The times they are a changin’” is the Bob Dylan song, indicating that the world is changing, including the publishing world (“You better start swimmin’ or you’ll sink like a stone”). In my home country, the Netherlands, the government wants all researchers to publish open access, so that everyone can read the outcome of studies financed by the government. As a researcher, you want everyone to be able to read what you have work on and discovered. The same holds true for the publisher.
We wish Prof. Dr. Ger Rijkers every success in his new position, and we look forward to his contributions to the journal.
28 February 2026
MDPI INSIGHTS: The CEO’s Letter #32 - MDPI China and Thailand, China Science Daily, 1,000 Partnerships, R2R
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts

Reflections from China: Year-End-Celebrations and Open Access Publishing
In February, I had the pleasure of joining over a thousand colleagues from our Tongzhou and Haidian offices at their end-of-year annual celebration in Beijing.
Spending time with our teams in China is also a powerful reminder of the scale and complexity of MDPI as a global organization. Our colleagues in Beijing, Wuhan, and across the country play a significant role in our day-to-day operations and long-term development. I’m grateful for the hospitality, collaboration, and commitment shown by our managers and teams in China, alongside colleagues worldwide, who have helped steadily build MDPI, brick by brick, over the years.
Below are some data on Open Access (OA) publishing in China and our collaboration in this important research market.
Open Access Publishing in China
China has been the world’s leading country in research and review article publication volume since 2019, exceeding one million publications in 2025. Over the past five years, the gap between China and the second-ranked country, the United States, has continued to widen.
In 2025:
- 47% of China’s research output was published Open Access
- Of those OA publications, 76% were Gold Open Access (approximately 382,930 articles)
- The overall OA distribution remained stable compared with 2024, with Gold OA increasing by 1%
Over the past five years (2021–2025):
- China published 4,398,050 research and review articles
- Approximately 48% of this output was OA
According to Dimensions, when comparing the top 20 countries by publication volume (2021–2025):
- China ranks 1st worldwide in publication volume
- China ranks 9th in citation performance within this group (for comparison, the US ranks 2nd in publication volume and 10th in citation ranking)
- Average citations per article: 12.51
Among the top 10 universities globally by publication volume, six are Chinese institutions, alongside Harvard University (USA), the University of São Paulo (Brazil), the University of Toronto (Canada), and the University of Oxford (UK).

MDPI and China
China is an important and long-standing part of MDPI’s global publishing ecosystem:
- In 2025, MDPI was the largest fully Open Access publisher in China
- MDPI published 22% of China’s Gold Open Access output (82,133 papers)
- We received 290,999 submissions from China-affiliated authors and published 82,133 articles
- There are 8,500+ active Editorial Board Members based in China
- 64% (5,438) have an H-index above 26
- MDPI works with:
- 117 Editors-in-Chief
- 103 Section Editors-in-Chief
- 71 China-based institutions currently hold IOAP agreements with MDPI, seven of which rank among the top 10 Chinese institutions by publication volume
China's scale in research output means that the publishing platforms chosen by Chinese scholars will continue to influence the direction of scholarly publishing. At the same time, MDPI’s strength comes from its international collaboration, with colleagues, editors, reviewers, and authors working together across regions and disciplines.
Thank you to all our colleagues in China, and around the world, who support MDPI’s publishing activities across departments and help advance open access research every day.
Impactful Research

“Progress in open science is built through trust, dialogue, and relationships”
Behind the Scenes: A Conversation with China Science Daily
During my trip to Beijing, I also had the opportunity to visit China Science Daily and take part in an interview and broader exchange with their team in Beijing. Visits like this matter because progress in open science is built not only through platforms and infrastructure, but also through trust, dialogue, and relationships across research communities and regions.
China Science Daily: History Museum
As part of the visit, I was given a tour of their History Museum, which offers a thorough perspective on the evolution of China’s first science and technology newspaper, established in 1959. The exhibition highlights how the organization developed into a trusted institution connecting research with the public and policymakers. It was a helpful reminder that at the core of publishing is stewardship, credibility, and long-term public engagement with science.

An Open Exchange on Open Science
During the visit, I met with Dr. Zhao Yan, Editor-in-Chief of ScienceNet. We had an open and engaging conversation about MDPI’s role in Open Access, the evolution of open science globally, and the potential for more collaboration going forward. He especially appreciated the candid and personal nature of our exchange, noting that this kind of dialogue feels important in a landscape where trust and transparency matter.

Interview on Open Access
I also participated in an interview with Ms. Yan Jie, from the Online Media Center and Editor-in-Chief of ScienceNet, China Science Daily. Our discussion covered the growth of Open Access over the past 30 years, MDPI’s mission and values, academic integrity, collaboration with the Chinese research community, and MDPI’s own 30th anniversary milestone. It was a great opportunity to reflect on how open science has matured, and where shared responsibility across publishers, institutions, and researchers continues to matter most.
“Progress in open science is built by more than scale and infrastructure”
I’m sharing a few photos from the visit as a glimpse behind the scenes. The full interview will be published by China Science Daily in due course, and I look forward to sharing it when it is available.

More broadly, visits like this reinforce something I’ve always believed in: progress in open science is built not only through scale and infrastructure, but also through continued dialogue, mutual respect, collaboration, and a willingness to listen across regions and perspectives. That remains central to our work, especially as MDPI reflects on 30 years of publishing, built together.
Inside MDPI

Bangkok Visit: Growth, Partnership, and Local Impact
In February, I also had the opportunity to visit our Bangkok office for the second time in two years to support their local meetings and deliver a training session on how we present MDPI at a corporate level.
It’s easy to spend time with our colleagues in Thailand. From Editorial and Production to Conferences, Marketing, Design, and our Regional Journal Relations Specialist (RJRS), the team continues to grow in scale and professionalism. I’d also like to recognize our local management and admin teams, who have been steadily expanding our office and supporting more than 500 colleagues on the ground.
Academic Partnerships
During the visit, we met with the Engineering Department at King Mongkut’s Institute of Technology Ladkrabang (KMITL). Our discussion focused on the recent MDPI developments, Institutional Open Access Program (IOAP) opportunities, Author Publishing Workshops (APW), and the potential use of JAMS to support their institutional journal.

“MDPI is the third-largest OA publisher in Thailand”
We also shared insights into the growth of Open Access (OA) in Thailand and KMITL’s own publishing trends. These conversations matter because institutions are looking for sustainable ways to support their researchers. Our IOAP agreements are one simple example of how we can provide value in this area while maintaining accessibility for authors.
Thailand and MDPI: 2025 Snapshot
Our Bangkok office, officially launched in 2022, has been growing to support over 500 staff members while continuing to expand its engagement in scholar visits, workshops, and conference collaborations. As at 2025, Thailand submissions to MDPI have increased about 21% and publications by about 25%, maintaining a rejection rate close to the company average. MDPI is the third-largest OA publisher in Thailand, publishing 15% of all Gold OA output in 2025.
Representing MDPI Externally
During the visit, I delivered a training session on how we present MDPI at external events.

This session covered topics related to:
- Our aim and guiding principles
- High-level company milestones and Indexing facts and figures
- Industry partnerships and collaborations
- Market trends in OA and subscription publishing
- Country-specific publishing data and collaborations with MDPI
- Insights from our Voice of Community report
I find that while many colleagues are very familiar with the specific journal for which they have responsibility, fewer have visibility into the broader MDPI ecosystem and the company’s global positioning. These sessions help build alignment, confidence, and consistency in how we represent the company.
What stands out most is that MDPI’s growth is not abstract: it’s visible in the people, the partnerships, and the professionalism developing across our offices.
Coming Together for Science

1,000 Institutional Partners: A Milestone Built on Trust
This month, we reached an important milestone: more than 1,000 institutions worldwide are now part of MDPI’s Institutional Open Access Program (IOAP). On paper, that is a number. In practice, it represents trust.
This milestone symbolizes thousands of conversations with libraries and institutions. It stands for negotiations, renewals, consortium expansions, and, most importantly, relationships built over time. It reflects the work of colleagues across publishing, institutional partnerships, marketing, editorial, finance, and many other teams who contribute to making these agreements operational.
In 2025 alone, more than 61,300 research articles benefited from article processing charge (APC) discounts through IOAP agreements. Tens of thousands of authors were able to publish through a simplified and structured process. At the same time, institutional administrators gained clearer oversight and streamlined workflows.

Why IOAP Matters
When we launched IOAP, the objective was straightforward: to reduce barriers for researchers while supporting institutions in navigating the evolving OA landscape. Over the past decade, the research ecosystem has changed. Funder mandates, national policies, and Plan S–aligned requirements have accelerated the transition to OA.
Institutions need publishing partners who provide transparency, scalability, and operational efficiency. IOAP was designed to support that reality.
For colleagues who would like to better understand the program, this blog-post overview of MDPI’s IOAP provides additional context, including common questions around the transition to OA and how our institutional partnerships are structured.
“Institutions need publishing partners who provide transparency, scalability, and operational efficiency”
Recent Examples
Our agreements continue to evolve across regions:
- In Sweden, MDPI signed a national Open Access publishing agreement with 96 institutions, enabling affiliated researchers to publish without managing individual APC payments.
- In Spain, we extended our flat-fee agreement with Universidad Católica de Valencia, reinforcing institutional support for OA publishing.
These examples show that institutions seek structured, predictable models that support their researchers at scale.
Looking Ahead
Crossing the threshold of 1,000 partners tells us that institutions see MDPI not just as a publisher but as a reliable operational partner in advancing open science. This milestone is not a finish line. It is a reminder that the work continues.
Thank you to the entire IOAP team and to all colleagues who contributed to reaching this achievement.
P.S. You can read about this milestone across industry outlets, including STM Publishing News, ALPSP, Research Information, EurekAlert, Brightsurf, among others. You can also read about the coverage in Poland (e.g., media-room, bomega) Korea (newstap), and Romania (EduLike).
Closing Thoughts

Reflections from the Researcher to Reader Conference
During 24–25 February, I attended the 2026 Researcher to Reader Conference in London, UK. Leaders from across scholarly publishing, research infrastructure, libraries, and technology gathered to discuss AI and research integrity, peer review reform, metadata and infrastructure, community engagement, open research policy, and the evolving role of publishers in a rapidly shifting ecosystem.
The conversations were open and honest, and at times uncomfortable – exactly what we need at times. Below are a few reflections that stayed with me.
The Battle for Knowledge: What Becomes Accepted as ‘True’?
One recurring theme was not whether science evolves but whether our infrastructure is resilient enough to sustain trust at scale. Science does not promise certainty: it promises process. As publishing systems grow more complex and become more technologically mediated, the question is how intentionally we design, monitor, and strengthen that process.
Peer Review: Speed, Credentials, and Structural Loops
Researchers consistently call for faster peer review. At the same time, reviewer credentials are often tied to publication records. This creates a structural loop. Publishing history opens reviewing opportunities, reviewing strengthens credentials, and those without early access remain outside the cycle.
There is a need for us to reflect on how opportunity circulates within our systems: we should ask how we create more inclusive pathways for researchers globally to participate in peer review.
Community Engagement Workshop
One of the highlights of R2R was the workshop format, whereby small groups met repeatedly over two days and moved from ideas to tangible strategies.
I joined the Community Engagement workshop led by Lou Peck (CEO at The International Bunch) and Godwyns Onwuchekwa (Principal Consultant at Global Tapestry Consulting). We explored two deceptively simple questions: What is a community? and What does engagement truly mean?
“Engagement requires shared design and shared responsibility”
Too often, organizations equate communication with engagement. The framework discussed mapped a maturity spectrum – from enablement (broadcasting, informing and consulting) to true engagement (collaborating and co-creating).
It was a useful reminder of the fact that if we want trust and loyalty, engagement must go beyond announcements and surveys. It requires shared design and shared responsibility.
AI: Democratization or Digital Colonialism?
I especially enjoyed the thought-provoking presentation from Nikesh Gosalia (Chief Partnership Officer at Cactus Communications), which highlighted an uncomfortable reality:

- 93% of AI-generated content is in English
- Approximately 2% is in French
- Approximately 2% is in German
- More than 7,000 languages are represented in less than 5% of the content within large AI systems
The implications are profound. Is AI democratizing access to scholarly publishing (making it easier for researchers everywhere to participate in global knowledge production)? Or are we encoding colonialism at scale (entrenching linguistic and structural hierarchies, and making it harder for voices from the Global South to be heard)?
AI is already reshaping how research is created, reviewed, discovered, and shared. Its potential is enormous. But its impact depends not only on capability, but on governance, design, and intentionality. Publishers, funders, and researchers all share responsibility in shaping how these systems evolve.
Ethicality in practice (Lightening Talk)

It was also great to have our colleague Dr Miloš Čučulović (Head of Technology Innovation at MDPI) present MDPI’s Ethicality platform during a lightning talk.
“Technology alone is not the answer”
Ethicality embeds AI-driven checks directly into the submission workflow, supporting editors proactively rather than reacting after publication. As we scale, tools like this help balance trust, efficiency, and research integrity.
This goes back into the underlying theme of the conference that technology alone is not the answer. However, technology embedded thoughtfully within clear governance frameworks can strengthen confidence in the editorial process.
Final thought
The question is no longer whether technology will transform research infrastructure: it is already doing so. The real question is what role each of us will play in shaping that transformation deliberately, with structural maturity, inclusive governance, and engagement that moves from informing to co-creating.
Science needs to evolve, responsibly. And that responsibility extends not only to what we publish, but also to how the systems behind publication are designed. Some important topics to continue reflecting on both internally and within our broader community.
Chief Executive Officer
MDPI AG
27 February 2026
Vaccines | Editor’s Choice Papers in 2024 (III)
1. “Hybrid Immunity against SARS-CoV-2 Variants: A Narrative Review of the Literature”
by Panagiota Tsagkli, Maria Geropeppa, Ioanna Papadatou and Vana Spoulou
Vaccines 2024, 12(9), 1051; https://doi.org/10.3390/vaccines12091051
Available online: https://www.mdpi.com/2076-393X/12/9/1051
2. “Lessons from Recent Measles Post-Campaign Coverage Surveys Worldwide”
by M. Carolina Danovaro-Holliday, Mitsuki Koh, Claudia Steulet, Dale A. Rhoda and Mary Kay Trimner
Vaccines 2024, 12(11), 1257; https://doi.org/10.3390/vaccines12111257
Available online: https://www.mdpi.com/2076-393X/12/11/1257
3. “Childhood Mandatory Vaccinations: Current Situation in European Countries and Changes Occurred from 2014 to 2024”
by Sara Farina, Alessandra Maio, Maria Rosaria Gualano, Walter Ricciardi and Leonardo Villani
Vaccines 2024, 12(11), 1296; https://doi.org/10.3390/vaccines12111296
Available online: https://www.mdpi.com/2076-393X/12/11/1296
4. “Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans”
by Alina Tscherne, Georgia Kalodimou, Alexandra Kupke, Cornelius Rohde, Astrid Freudenstein, Sylvia Jany, Satendra Kumar, Gerd Sutter, Verena Krähling, Stephan Becker and Asisa Volz
Vaccines 2024, 12(12), 1316; https://doi.org/10.3390/vaccines12121316
Available online: https://www.mdpi.com/2076-393X/12/12/1316
5. “The Strategic Advisory Group of Experts (SAGE) on Immunization—Past, Present and Future”
by Melanie Marti, Hanna Nohynek, Philippe Duclos, Katherine L. O’Brien and Joachim Hombach
Vaccines 2024, 12(12), 1402; https://doi.org/10.3390/vaccines12121402
Available online: https://www.mdpi.com/2076-393X/12/12/1402
6. “Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus”
by Philip Hicks, Tomaz B. Manzoni, Jonna B. Westover, Raegan J. Petch, Brianne Roper, Brian B. Gowen and Paul Bates
Vaccines 2024, 12(12), 1403; https://doi.org/10.3390/vaccines12121403
Available online: https://www.mdpi.com/2076-393X/12/12/1403
7. “Development Using Bioluminescence Imaging of a Recombinant Anguillid Herpesvirus 1 Vaccine Candidate Associated with Normal Replication In Vitro but Abortive Infection In Vivo”
by Haiyan Zhang, Arun Sridhar, Natacha Delrez, Bo He, Sophie Fourny, Yuan Gao, Owen Donohoe and Alain F. C. Vanderplasschen
Vaccines 2024, 12(12), 1423; https://doi.org/10.3390/vaccines12121423
Available online: https://www.mdpi.com/2076-393X/12/12/1423
8. “Immunoprophylaxis with MV140 Is Effective in the Reduction of Urinary Tract Infections—A Prospective Real-Life Study”
by Filipe Abadesso Lopes, Miguel Miranda, André Ye, Joana Rodrigues, Paulo Pé-Leve, José Palma Reis and Ricardo Pereira e Silva
Vaccines 2024, 12(12), 1426; https://doi.org/10.3390/vaccines12121426
Available online: https://www.mdpi.com/2076-393X/12/12/1426
9. “Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2”
by Achilleas Livieratos, Lars Erik Schiro, Charalambos Gogos and Karolina Akinosoglou
Vaccines 2024, 12(12), 1444; https://doi.org/10.3390/vaccines12121444
Available online: https://www.mdpi.com/2076-393X/12/12/1444
10. “Transforming Aquaculture through Vaccination: A Review on Recent Developments and Milestones”
by Iosif Tammas, Konstantina Bitchava and Athanasios I. Gelasakis
Vaccines 2024, 12(7), 732; https://doi.org/10.3390/vaccines12070732
Available online: https://www.mdpi.com/2076-393X/12/7/732
11. “Implementation of mRNA–Lipid Nanoparticle Technology in Atlantic Salmon (Salmo salar)”
by Lars Ole Sti Dahl, Sjoerd Hak, Stine Braaen, Alicja Molska, Francesca Rodà, Jeremie Parot, Øystein Wessel, Johanna Hol Fosse, Håvard Bjørgen, Sven Even Borgos and Espen Rimstad
Vaccines 2024, 12(7), 788; https://doi.org/10.3390/vaccines12070788
Available online: https://www.mdpi.com/2076-393X/12/7/788
12. “The Problem with Delaying Measles Elimination”
by Natasha S. Crowcroft, Anna A. Minta, Shelly Bolotin, Tania Cernuschi, Archchun Ariyarajah, Sébastien Antoni, Mick N. Mulders, Anindya S. Bose and Patrick M. O’Connor
Vaccines 2024, 12(7), 813; https://doi.org/10.3390/vaccines12070813
Available online: https://www.mdpi.com/2076-393X/12/7/813
25 February 2026
Vaccines | Editor’s Choice Papers in 2024 (II)
1. “Development and Evaluation of an Immunoinformatics-Based Multi-Peptide Vaccine against Acinetobacter baumannii Infection”
by Sean Jeffreys, Megan P. Tompkins, Jadelynn Aki, Sara B. Papp, James P. Chambers, M. Neal Guentzel, Chiung-Yu Hung, Jieh-Juen Yu and Bernard P. Arulanandam
Vaccines 2024, 12(4), 358; https://doi.org/10.3390/vaccines12040358
Available online: https://www.mdpi.com/2076-393X/12/4/358
2. “Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study”
by Guillermo Ezpeleta, Ana Navascués, Natividad Viguria, Mercedes Herranz-Aguirre, Sergio Enrique Juan Belloc, Juan Gimeno Ballester, Juan Carlos Muruzábal, Manuel García-Cenoz, Camino Trobajo-Sanmartín, Aitziber Echeverria et al.
Vaccines 2024, 12(4), 383; https://doi.org/10.3390/vaccines12040383
Available online: https://www.mdpi.com/2076-393X/12/4/383
3. “Design and Characterization of a New Formulation for the Delivery of COVID-19-mRNA Vaccine to the Nasal Mucosa”
by Ayça Altay Benetti, Eugene Yang Zhi Tan, Zi Wei Chang, Ki Hyun Bae, Ma Thinzar Thwin, Ram Pravin Kumar Muthuramalingam, Kuo-Chieh Liao, Yue Wan, Lisa F. P. Ng, Laurent Renia et al.
Vaccines 2024, 12(4), 409; https://doi.org/10.3390/vaccines12040409
Available online: https://www.mdpi.com/2076-393X/12/4/409
4. “Impact of HPV Vaccination on the Incidence of High-Grade Cervical Intraepithelial Neoplasia (CIN2+) in Women Aged 20–25 in the Northern Part of Norway: A 15-Year Study”
by Marte Pettersen Mikalsen, Gunnar Skov Simonsen and Sveinung Wergeland Sørbye
Vaccines 2024, 12(4), 421; https://doi.org/10.3390/vaccines12040421
Available online: https://www.mdpi.com/2076-393X/12/4/421
5. “mRNA Vaccine for Alzheimer’s Disease: Pilot Study”
by Armine Hovakimyan, Garri Chilingaryan, Olga King, Joia Kai Capocchi, Jean Paul Chadarevian, Hayk Davtyan, Roman Kniazev, Michael G. Agadjanyan and Anahit Ghochikyan
Vaccines 2024, 12(6), 659; https://doi.org/10.3390/vaccines12060659
Available online: https://www.mdpi.com/2076-393X/12/6/659
6. “An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity”
by Emma Chang-Rabley, Menno C. van Zelm, Emily E. Ricotta and Emily S. J. Edwards
Vaccines 2024, 12(6), 675; https://doi.org/10.3390/vaccines12060675
Available online: https://www.mdpi.com/2076-393X/12/6/675
7. “Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas”
by Kawaljit Kaur, Jashan Sanghu, Sanaz Memarzadeh and Anahid Jewett
Vaccines 2024, 12(6), 677; https://doi.org/10.3390/vaccines12060677
Available online: https://www.mdpi.com/2076-393X/12/6/677
8. “The Influence of SARS-CoV-2 Vaccination on the Mortality and Outcomes of Patients with Both Myocardial Infarction and COVID-19”
by Eugeniusz Hrycek, Anna Walawska-Hrycek, Krzysztof Milewski, Przemysław Nowakowski, Piotr Buszman and Aleksander Żurakowski
Vaccines 2024, 12(9), 983; https://doi.org/10.3390/vaccines12090983
Available online: https://www.mdpi.com/2076-393X/12/9/983
9. “Immunogenicity and Protective Efficacy of a Multi-Antigen Mycobacterium tuberculosis Subunit Vaccine in Mice”
by Annuurun Nisa, Rachel Pinto, Warwick J. Britton, James A. Tricca and Claudio Counoupas
Vaccines 2024, 12(9), 997; https://doi.org/10.3390/vaccines12090997
Available online: https://www.mdpi.com/2076-393X/12/9/997
10. “The Major Role of T Regulatory Cells in the Efficiency of Vaccination in General and Immunocompromised Populations: A Review”
by Stanislaw Stepkowski, Dulat Bekbolsynov, Jared Oenick, Surina Brar, Beata Mierzejewska, Michael A. Rees and Obi Ekwenna
Vaccines 2024, 12(9), 992; https://doi.org/10.3390/vaccines12090992
Available online: https://www.mdpi.com/2076-393X/12/9/992
11. “Hepatitis E Vaccines Updates”
by Christopher Hartley, Paul Wasuwanich, Trung Van and Wikrom Karnsakul
Vaccines 2024, 12(7), 722; https://doi.org/10.3390/vaccines12070722
Available online: https://www.mdpi.com/2076-393X/12/7/722
12. “Buccal Administration of a Zika Virus Vaccine Utilizing 3D-Printed Oral Dissolving Films in a Mouse Model”
by Sarthak Shah, Parth Patel, Amarae Ferguson, Priyal Bagwe, Akanksha Kale, Emmanuel Adediran, Revanth Singh, Tanisha Arte, Dedeepya Pasupuleti, Mohammad N. Uddin et al.
Vaccines 2024, 12(7), 720; https://doi.org/10.3390/vaccines12070720
Available online: https://www.mdpi.com/2076-393X/12/7/720




















